



FORMULATION AND EVALUATION OF PEDIATRIC
CARBAMAZEPINE SUSTAINED RELEASE ORAL
JELLY

BY

SAEID MEZAIL MAWAZI

A thesis submitted in fulfilment of the requirement for
the degree of Master in Pharmaceutical Sciences
(Pharmaceutical Technology)

Kulliyyah of Pharmacy
International Islamic University Malaysia

JANUARY 2018

ABSTRACT

Once daily epilepsy carbamazepine (CBZ) medication oral jelly for pediatrics was prepared and evaluated. The available marketed CBZ pediatric dosage form is CBZ suspension only which is not sustained release medication. Therefore, developing new CBZ sustained release oral jelly can play an important role to handle the following issues; (1) suitable dosage form for easy swallowing (2) reducing the multiple daily doses to one daily dose for patient convenience. This work consists of three parts, first one is to prepare CBZ sustained release microparticles, the second part is to incorporate the microparticles in alginate beads and the final one is to suspend the beads in oral jelly. The microparticles prepared by solvent evaporation method utilizing EC as sustained release polymer. Microparticles were evaluated for particle size, encapsulation efficiency (EE), *in vitro* release test, differential scanning calorimetry (DSC), attenuated total reflection–fourier transform infrared spectroscopy (ATR-FTIR), and high-pressure liquid chromatography (HPLC). CBZ release from microparticles was achieved and compared to the release of CBZ sustained release tablets of 200 mg stated in United States Pharmacopoeia (USP). The beads fabricated by crosslinking of sodium alginate with calcium chloride solution utilizing electrospray. CBZ beads were tested for the size, morphology, *in vitro* drug release and HPLC. *In vitro* release study results of CBZ from the beads showed the same release of CBZ in microparticles. Finally, the CBZ oral jelly prepared using an iota carrageenan gelling agent and evaluated for the dissolution test, syneresis, rheology, drug content uniformity, viscosity, physical appearance, and stability. CBZ loaded microparticle size ranged from 131 to 186 μm . The highest EE was 96% for MP2 and the lowest one was 74% for MP9. The cumulative release percentage of CBZ at 24 h was ranged from 49% in MP1 and 89% in MP10. CBZ bead results showed bead size of 1.4 mm for B2 and 3.5 mm for B4 with same EE of CBZ loaded microparticles. The release of CBZ from its beads was almost equal for all prepared bead formulations. *In vitro* drug release of CBZ was done firstly in the same conditions of dissolution test of CBZ beads and CBZ microparticles to ensure that there was no change in the release of CBZ when fabricated in iota carrageenan jelly. Secondly, comparison dissolution test study was carried out between CBZ oral jelly and Tegretol® XR 200 mg tablets and similarity factor was calculated to ensure that the CBZ jelly matching to the guidelines. Stable and homogenize CBZ oral jelly was obtained with the release similarity factor (F2) of 76 between CBZ oral jelly and Tegretol® XR 200 mg tablets under the same release conditions. The release of CBZ from the jelly found to be 94.11% from the original concentration after 24 hours. This study developed a new CBZ dosage form for pediatric patients with sustained release property and could be used as main and alternative treatment for pediatric epilepsy patients.

خلاصة البحث

بسبب عدم توفر دواء الكاربامازين ذو الامتصاص البطيء للاطفال تم تحضير وفحص كاربامازين الاطفال ذو الامتصاص البطيء الذي يمكن ان يلعب دورا هاما في علاج الكثير من المشاكل , ابرزها (1) شكل علاجي جديد يسهل من عملية البلع (2) تقليل عدد الجرعات اليومية لدواء الكاربامازين الاعتيادي من عدة جرعات الى جرعة واحدة حيث يسهل استخدام الدواء سواء للمريض او المرافق له. هذا المشروع او البحث يتكون من ثلاثة اجزاء رئيسية وهي: الجزء الاول متضمنا تحضير الكاربامازين على شكل حبيبات مجهرية صغيرة تتضمن تحرير الدواء ببطيء. الجزء الثاني هو تغليف حبيبات الكاربامازين المجهرية الصغيرة في كرات الجينات الصوديوم والجزء الاخير هو لتعليق كرات الجينات الصوديوم في هلام الكاراجينان. تحضير الجزء الاول وهو حبيبات الكاربامازين المجهرية الصغيرة كان باستخدام طريقة تبخير المذيب باستخدام الايثايل سليولوز كبوليمر يساعد على عملية تحرير الدواء ببطيء. تقييم وفحص حبيبات الكاربامازين الصغيرة كان باستخدام فحص تحرير الدواء, فحص كفاءة التغليف, فحص حجم الحبيبات, فحص شكل الحبيبات, المسح الحراري التفاضلي , الضغط العالي لفصل السوائل, وفحص طيف الاشعة تحت الحمراء. اظهرت نتائج فحص الحبيبات المجهرية لدواء الكاربامازين تطابقا جيدا مع فحص تحرير الدواء من اقراص الكاربامازين 200 ملغم المنصوص عليها في دستور الادوية الامريكي تحت نفس الظروف. تحضير كرات الجينات الصوديوم كان باستخدام تقنية التوزيع الكهربائي لاجنيت الصوديوم في محلول الكالسيوم كلورايد عن طريق تكوين كرات صلبة بفضل تشعب محلول الكالسيوم كلورايد مع الصوديوك الجنيت المخلوط مع حبيبات الكاربامازين المجهرية الصغيرة. كرات الجنيت الصوديوم المتكونة كانت قد فحصت لشكلها الخارجي , حجمها, فحص تحرير الكاربامازين من هذه الكرات اولا ثم من حبيبات الايثايل سليولوز ثانيا, فحص الضغط العالي لفصل السوائل. نتائج فحص تحرير الكاربامازين من كرات الاجنيت كانت مطابقة للخطوة السابقة من التحضير مما يدل على ان الخطوة الثانية لم تغير تحرير الكاربامازين اثناء تغليفه بكرات الجنيت الصوديوم. الخطوة الاخيرة من هذا المشروع تضمن تعليق كرات الصوديوم الجنيت داخل هلام الايوتا كاراجينان حيث تم تقييم هلام الايوتا كاراجينان اولا بفحص الخواص الجريانية لهذا الهلام, فحص فصل الماء عن الهلام اثناء الحزن, فحص المظهر الخارجي للهلام, فحص لزوجة الهلام , فحص تحرير الكاربامازين من الهلام واخيرا اختبار الضغط العالي لفصل السوائل.

APPROVAL PAGE

I certify that I have supervised and read this study and that in my opinion, it conforms to acceptable standards of scholarly presentation and is fully adequate, in scope and quality, as a thesis for the degree of Master in Pharmaceutical Sciences (Pharmaceutical Technology).

.....
Abd Almonem Doolaanea
Supervisor

.....
Hazrina Ab Hadi
Co-Supervisor

I certify that I have read this study and that in my opinion it conforms to acceptable standards of scholarly presentation and is fully adequate, in scope and quality, as a thesis for the degree of Master in Pharmaceutical Sciences (Pharmaceutical Technology).

.....
Bappaditya Chatterjee
Internal Examiner

.....
Haliza Katas
External Examiner

This thesis was submitted to the Department of Pharmaceutical Technology and is accepted as a fulfilment of the requirement for the degree of Master in Pharmaceutical Sciences (Pharmaceutical Technology).

.....
Mohd. Rushdi
Head, Department of
Pharmaceutical Technology

This thesis was submitted to the Kulliyah of Pharmacy and is accepted as a fulfilment of the requirement for the degree of Master in Pharmaceutical Sciences (Pharmaceutical Technology).

.....
Juliana Bt. Md. Jaffri
Dean, Kulliyah of Pharmacy

DECLARATION

I hereby declare that this thesis is the result of my own investigations, except where otherwise stated. I also declare that it has not been previously or concurrently submitted as a whole for any other degrees at IIUM or other institutions.

Saeid Mezail Mawazi

Signature.....

Date

INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA

**DECLARATION OF COPYRIGHT AND AFFIRMATION OF
FAIR USE OF UNPUBLISHED RESEARCH**

**FORMULATION AND EVALUATION OF PEDIATRIC
CARBAMAZEPINE SUSTAINED RELEASE ORAL JELLY**

I declare that the copyright holder of this thesis is Saeid Mezail Mawazi

Copyright ©2018 by Saeid Mezail Mawazi. All rights reserved.

No part of this unpublished research may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior written permission of the copyright holder except as provided below

1. Any material contained in or derived from this unpublished research may only be used by others in their writing with due acknowledgement.
2. IIUM or its library will have the right to make and transmit copies (print or electronic) for institutional and academic purpose.
3. The IIUM library will have the right to make, store in a retrieval system and supply copies of this unpublished research if requested by other universities and research libraries.

By signing this form, I acknowledged that I have read and understand the IIUM Intellectual Property Right and Commercialization policy.

Affirmed by Saeid Mezail Mawazi

.....
Signature

.....
Date

ACKNOWLEDGEMENTS

I would like to express my sincerest gratitude to my supervisor, Asst. Prof. Dr. Abd Almonem Doolaanea for giving me the opportunity to work on such a significant and interesting project. Without his invaluable support, guidance, and encouragement, this journey would not have been possible. I greatly appreciate his continuous faith in my abilities which has truly enabled me to expand my horizons.

I would like to thank my second advisor, Asst. Prof. Dr. Hazrina Ab Hadi for accommodating my own interests and for her understanding my patience for my research and giving me support for what I have done.

My wholehearted thanks to all my lab-mates Samah Hamed, Hamzeh Alkhatib, Mohammad Nasrin Bin Abdul Rahman, Luqman Muizzuddin Bin Mohd Rosli, Mohd. Fakhrol Radzi Bin Mamat, Irda Haslinda Binti Hassan, all PG Office members and Pharmaceutical Technology Department members for their invaluable help, advice and information. I would like to thank all my close friends, who always stood by my side.

Finally, I would like to give my special thanks to my family members for their unconditional love and support and my father in law Dr. Mazin Najeeb for his advice and support. I would like to dedicate my thesis to my wife, Halah, for always letting my dreams come true.

TABLE OF CONTENTS

| | |
|--|----------|
| Abstract | ii |
| Abstract in Arabic | iii |
| Approval page | iv |
| Declaration | v |
| Declaration of copyright and affirmation of fair use of unpublished research | vi |
| Acknowledgements | vii |
| Table of Contents | viii |
| List of Tables | xii |
| List of Figures | xiii |
| List of Abbreviation | xv |
| List of Symbols | xvi |
| CHAPTER ONE: INTRODUCTION | 1 |
| Introduction | 1 |
| 1.1 Background | 1 |
| 1.2 Problem Statement | 3 |
| 1.3 Hypothesis | 4 |
| 1.4 Objective | 4 |
| 1.5 Study Design | 4 |
| CHAPTER TWO: LITERATURE REVIEW | 6 |
| 2.1 Introduction | 6 |
| 2.2 Pharmacological development of pediatric population | 6 |
| 2.2.1 Absorption | 7 |
| 2.2.1.1 Oral | 7 |
| 2.2.1.2 Buccal | 7 |
| 2.2.1.3 Topical | 7 |
| 2.2.1.4 Intramuscular | 8 |
| 2.2.1.5 Pulmonary | 8 |
| 2.2.1.6 Rectal | 8 |
| 2.2.1.7 Nasal | 8 |
| 2.2.1.8 Distribution | 8 |
| 2.2.1.9 Body Water/Fat | 9 |
| 2.2.1.10 Protein Binding | 9 |
| 2.2.2 Metabolism | 9 |
| 2.2.3 Renal Elimination | 10 |
| 2.3 Pediatric Preparations | 10 |
| 2.4 Sustained Release Formulations | 12 |
| 2.5 Oral Jelly as a Dosage Forms | 14 |
| 2.6 Carbamazepine | 16 |
| 2.7 Microencapsulation | 19 |
| 2.8 Polymers and Gelling Agents | 20 |
| 2.8.1 Ethyl Cellulose | 21 |
| 2.8.2 Sodium Alginate | 23 |
| 2.9 Alginate Beads | 23 |

| | |
|--|-----------|
| 2.10 Electropray Technique..... | 25 |
| CHAPTER THREE: CARBAMAZEPINE MICROPARTICLES..... | 26 |
| 3.1 Introduction..... | 26 |
| 3.2 Materials and Methods..... | 28 |
| 3.2.1 Materials..... | 28 |
| 3.2.2 Preparation of CBZ Microparticles..... | 28 |
| 3.2.2.1 Preparation of Aqueous Phase..... | 28 |
| 3.2.2.2 Preparation of Organic Phase..... | 28 |
| 3.2.2.3 Preparation of the Primary Emulsion..... | 29 |
| 3.2.3 Particle Size Determination..... | 29 |
| 3.2.4 Encapsulation Efficiency (EE)..... | 30 |
| 3.2.5 <i>In Vitro</i> Drug Release..... | 30 |
| 3.2.6 Validation of UV-Vis Method..... | 31 |
| 3.2.6.1 Solution Preparation..... | 31 |
| 3.2.6.2 Spectrophotometric Method Validation..... | 31 |
| 3.2.6.3 Specificity and Solution Stability..... | 32 |
| 3.2.6.4 Linearity..... | 32 |
| 3.2.6.5 Accuracy..... | 32 |
| 3.2.6.6 Precision..... | 33 |
| 3.2.7 DSC Analysis..... | 33 |
| 3.2.8 ATR-FTIR Analysis..... | 34 |
| 3.2.9 HPLC Analysis..... | 34 |
| 3.2.10 Morphology Study..... | 34 |
| 3.2.11 Experimental Design and Statistical Analysis..... | 35 |
| 3.3 Results..... | 36 |
| 3.3.1 Particle Size..... | 36 |
| 3.3.2 Encapsulation Efficiency..... | 38 |
| 3.3.3 <i>In Vitro</i> Drug Release..... | 39 |
| 3.3.4 Method Validation..... | 43 |
| 3.3.4.1 Specificity..... | 43 |
| 3.3.4.2 Solution Stability..... | 44 |
| 3.3.4.3 Linearity..... | 45 |
| 3.3.4.4 Accuracy..... | 46 |
| 3.3.4.5 Precision..... | 47 |
| 3.3.5 DSC Analysis..... | 48 |
| 3.3.6 HPLC..... | 50 |
| 3.3.7 FTIR..... | 52 |
| 3.3.8 Morphological Studies..... | 53 |
| 3.4 Discussion..... | 54 |
| 3.5 Conclusion..... | 61 |
| CHAPTER FOUR: CARBAMAZEPINE BEADS..... | 62 |
| 4.1 Introduction..... | 62 |
| 4.2 Materials and Methods..... | 65 |
| 4.2.1 Materials..... | 65 |
| 4.2.2 Design of Experiment..... | 65 |
| 4.2.3 Preparation of Sodium Alginate Solution..... | 65 |
| 4.2.4 Preparation of Calcium Chloride Solution..... | 66 |

| | |
|---|------------|
| 4.2.5 Preparation of Beads | 66 |
| 4.2.6 Characterization of the Beads | 67 |
| 4.2.6.1 Bead Size | 67 |
| 4.2.6.2 Surface Morphology Study..... | 67 |
| 4.2.6.3 Encapsulation Efficiency..... | 68 |
| 4.2.6.4 In Vitro Drug Release..... | 68 |
| 4.2.6.5 Interaction Study by HPLC | 68 |
| 4.3 Results..... | 69 |
| 4.3.1 Bead Size..... | 69 |
| 4.3.2 Morphology Study | 70 |
| 4.3.3 EE..... | 71 |
| 4.3.4 In Vitro Drug Release | 72 |
| 4.3.5 HPLC Analysis | 73 |
| 4.4 Discussion | 75 |
| 4.5 Conclusion | 78 |
| | |
| CHAPTER FIVE: PEDIATRICS CARBAMAZEPINE ORAL JELLY | 79 |
| 5.1 Introduction..... | 79 |
| 5.2 Material and Methods | 81 |
| 5.2.1 Material | 81 |
| 5.2.2 Design of Experiment | 81 |
| 5.2.3 Preparation of Carbamazepine Jelly..... | 81 |
| 5.2.4 Characterization of CBZ Oral Jelly..... | 82 |
| 5.2.4.1 Syneresis..... | 82 |
| 5.2.4.2 Rheology..... | 83 |
| 5.2.4.3 Homogeneity Test | 83 |
| 5.2.4.4 In vitro Drug Release..... | 84 |
| 5.2.4.5 Viscosity | 85 |
| 5.2.4.6 Physical Appearance | 85 |
| 5.2.4.7 HPLC Analysis | 85 |
| 5.2.4.8 Stability Study | 85 |
| 5.3 Results..... | 87 |
| 5.3.1 Syneresis | 87 |
| 5.3.2 Rheology | 87 |
| 5.3.3 Homogeneity Test..... | 89 |
| 5.3.4 In vitro Drug Release | 90 |
| 5.3.5 Physical Appearance | 91 |
| 5.3.6 HPLC Analysis | 91 |
| 5.3.7 Stability Study..... | 92 |
| 5.4 Discussion | 92 |
| 5.5 Conclusion | 96 |
| | |
| CHAPTER SIX: GENERAL CONCLUSION | 97 |
| | |
| REFERENCES..... | 101 |
| | |
| APPENDIX I: PARTICLE SIZE DISTRIBUTION OF MP1-MP16 FORMULATIONS GRAPHS | 113 |

| | |
|--|------------|
| APPENDIX II: FTIR SPECTRUM OF MP1-MP16 FORMULATIONS | 121 |
| APPENDIX III: RESEARCH OUTPUT | 129 |

LIST OF TABLES

| <u>Table No.</u> | | <u>Page No.</u> |
|------------------|--|-----------------|
| 3.1 | Release profile requirement of CBZ as USP | 31 |
| 3.2 | Factorial design of prepared CBZ-loaded microparticles | 35 |
| 3.3 | Results of EE, particle size, span, and % release of CBZ from microparticles formulations after 24 hours (n = 3) | 36 |
| 3.4 | Solution stability of CBZ in water, where A_{286} means absorbance reading at 286 nm wavelength | 45 |
| 3.5 | Accuracy study of CBZ spiked at different concentrations | 47 |
| 3.6 | Results of a precision study of CBZ at 100% concentration level. | 48 |
| 3.7 | Degree crystallinity of CBZ | 50 |
| 4.1 | Factorial design of prepared CBZ-beads formulations. | 67 |
| 4.2 | Results of bead size, EE and the % release of CBZ for 24 h for B1-B8 Formulations (n = 3) | 69 |
| 5.1 | J1 to J8 formulation of syneresis study | 82 |
| 5.2 | Results of syneresis test of J1-J8 formulations | 87 |
| 5.3 | Results of rheology study of iota carrageenan jelly | 88 |
| 5.4 | Homogeneity test results | 89 |
| 5.5 | Release of CBZ from the jelly in water dissolution medium | 90 |
| 5.6 | Dissolution test and similarity factor of Tegretol XR tablets and CBZ-oral jelly (n=3) | 90 |
| 5.7 | Stability study results | 92 |

LIST OF FIGURES

| <u>Figure No.</u> | | <u>Page No.</u> |
|-------------------|---|-----------------|
| 2.1 | Carbamazepine Structure | 16 |
| 3.1 | Effect of A (EC), B (PVA), C (solvent), D (homogenization speed) and E (homogenization time) factors on particle size for MP1-MP8 formulations | 37 |
| 3.2 | Effect of A (EC), B (PVA), C (solvent), D (homogenization time) and C (homogenization speed) factors on particle size for MP9-MP16 formulations | 37 |
| 3.3 | Effect of A (EC), B (PVA), C (solvent), D (homogenization time) and E (homogenization speed) factors on EE for MP1-MP8 formulations | 38 |
| 3.4 | Effect of A (EC), B (PVA), C (solvent), D (homogenization time) and E (homogenization speed) factors on EE for MP9-MP16 formulations | 39 |
| 3.5 | Effect of A (EC), B (PVA), C (solvent), D (homogenization time) and E (homogenization speed) factors on % Release Profile for 24 h of MP1-MP8 formulations | 40 |
| 3.6 | Effect of A (EC), B (PVA), C (solvent), D (homogenization time) and E (homogenization speed) factors on % release profile for 24 h of MP9-MP16 formulations | 41 |
| 3.7 | Release of CBZ from MP1-MP8 formulations for 24 h (n = 3) | 41 |
| 3.8 | Release of CBZ from MP9-MP16 formulations for 24 h (n = 3) | 42 |
| 3.9 | Effect of A (EC), B (PVA), C (solvent), D (homogenizing speed) and E (homogenization time) factors on % release profile for 24 h of MP9-MP16 | 42 |
| 3.10 | Release profile comparison between MP12 and CBZ only (control) for 24 h | 43 |
| 3.11 | UV-spectrum of CBZ, EC, and PVA | 44 |
| 3.12 | Linearity of CBZ | 46 |
| 3.13 | DSC thermogram of formulated microparticles, EC and CBZ. | 49 |
| 3.14 | HPLC chromatograms for standard CBZ, microparticles and blank | 51 |

| | | |
|------|--|----|
| 3.15 | FTIR of MP1-MP16 formulations | 52 |
| 3.16 | FTIR results of CBZ, EC and CBZ-microparticles (MP12) | 53 |
| 3.17 | Morphology of CBZ microparticles viewed under stereomicroscope connected to Nikon lens | 53 |
| 4.1 | Normal plot of the effect of different factors on formulated bead size | 70 |
| 4.2 | Main effect plot of different factors on the size of the formulated beads | 70 |
| 4.3 | Morphology of CBZ-bead a (B5), b (B4), c (B1), and d (B2) formulations | 71 |
| 4.4 | Effect plot of different factors on EE of prepared beads formulations | 72 |
| 4.5 | Release profile of CBZ from beads formulations | 73 |
| 4.6 | Normal plot of the effect of different factors on CBZ dissolution beads for 24 h | 73 |
| 4.7 | HPLC chromatogram of CBZ-standard and CBZ-beads | 74 |
| 5.1 | Rheology model of iota-carrageenan jelly 2.5% without beads | 88 |
| 5.2 | Rheology model of CBZ jelly | 89 |
| 5.3 | HPLC test of stability study for CBZ standard and CBZ-jelly | 91 |

LIST OF ABBREVIATION

| | |
|------|--|
| CBZ | Carbamazepine |
| EC | Ethylcellulose |
| MR | Modified release |
| EA | Ethyl acetate |
| PVA | Polyvinyl alcohol |
| EE | Encapsulation efficiency |
| DT | Dissolution test |
| PS | Particle size |
| EMA | European medicines agency |
| CHMP | Committee for medicinal products for human use |
| MR | Modified release |
| DSC | Differential scanning calorimetry |
| HPLC | High-pressure liquid chromatography |
| FTIR | Fourier transform infrared spectroscopy |
| MP | Microparticles |
| B | Beads |
| J | jelly |
| BBB | Blood-brain barrier |
| WHO | World health organization |
| HPMC | Hydroxypropylmethylcellulose |
| SF | Sphericity Factor |
| F2 | Similarity Factor |
| HCl | Hydrochloric acid |
| GIT | Gastro-intestinal tract |
| FDA | Food and drug administrative |
| USP | United states pharmacopoeia |

LIST OF SYMBOLS

| | |
|---|------------|
| ® | Trade name |
| ° | degree |
| p | P value |
| μ | micro |
| Σ | Sigma |

CHAPTER ONE

INTRODUCTION

1.1 BACKGROUND

Pharmaceutical dosage forms for pediatrics must be appropriate in relation to their age. Pediatrics below 6 years generally cannot have solid dosage forms by oral route unlike liquid and semi-solid dosage forms. According to European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), there is a number of important considerations to be noted when manufacturing a new dosage form for pediatrics and as following (Committee, 2006):

1. Minimizing the frequency of dosage.
2. Minimizing non-toxic excipients.
3. Reliable, easy, convenient administration.
4. Should be inexpensive and available commercially.
5. Should be easily prepared, elegant and stable.
6. One dosage form suits all or a full of a range of pediatrics.

EMA (CHMP) mentioned that modified release (MR) preparations can be helpful for child patients who may need to have medication when they are at school or in the night. In oral modified release medications, single dose daily formulations can be advantageous for compliance. While MR injections can minimize significantly the frequency of the dose but the pain must be avoided. Transdermal formulations can also prolong the effect of the drug with simple use but the skin permeability level will be different with age developmental changes and this issue must be taken in the consideration when preparing such a dosage form. MR formulations should meet the

requirements of the dose for a different range of ages. In the MR solid preparations, the dosage requirements can be achieved by using specified formulations like prolonged release granules with known dose per granule. Liquid MR dosage forms ingredients are dissolved in or be bound to very small particles like pellets or resin particles. MR oral suspensions contain pellets or small particles and size of that particles and pellets is limited and child patient must not chew it (Committee, 2006).

Epilepsy is one of a brain function disorders characterized mostly by frequent and unpredictable obstruction of the function of the normal brain, known as epileptic seizures. It's the abnormality of a sudden electrical activity (Fisher et al., 2005). This disorder is affecting about 70,000,000 worldwide of different ages in 2014 (Ali & Nabi, 2014). Different reasons were reported to know the causes behind epilepsy syndrome such as the zone of the brain involved, genetic reasons, age etc. (Berg, Levy, Testa, & Shinnar, 1999). There are many types of epilepsy syndrome like; Juvenile absence epilepsy, Angelman syndrome, childhood absence epilepsy, Doose syndrome, Dravet syndrome, epilepsy on infancy with migrating focal seizures, epilepsy with myoclonic absence, frontal lobe epilepsy, epilepsy with generalized tonic-clonic seizures alone, hypothalamic hamartoma, *lafora* progressive myoclonus epilepsy, PCDH19 epilepsy, and reflex epilepsy etc. (Kramer et al., 1998; U. Lee, Kim, & Jung, 2006).

CBZ is an anticonvulsant drug used to treat focal seizures, trigeminal, neuralgia, and bipolar disorder. The site of absorption of CBZ is the gastrointestinal tract (GIT) but it has faster absorption on a full stomach than an empty stomach. CBZ is a white or white-yellowish particles, bitter in taste, insoluble in water. CBZ shows its anticonvulsant or antiepileptic effect by inhibiting voltage-dependent sodium channel, thus it blocks sustained repetitive firing in individual neurons. It seems to

give no help in GABA-mediated inhibition (Catterall, 2014). Diplopia, headache, dizziness, nausea and vomiting are the common side effects of CBZ while the rare side effects of CBZ includes erythema multiform, Stevens-Johnson syndrome, Reversible mild leucopenia, blood dyscrasias and toxic hepatitis (Perucca & Gilliam, 2012).

Jellies can be defined as "a semisolid system consisting of either suspension made up of gelling agent molecules interpenetrated by a liquid" (Jones, Swarbrick, & Boylan, 2002). Medicated jellies more reasonable for pediatric, many studies have suggested that the using of oral semi-solid dosage forms are preferred for dysphagic, children and geriatric patients because of their formulation's nature as semi-solid preparations (Yutaka Inoue & Kanamotoa, 2015). Oral jelly is a fundamental solution to dysphagia patients, and also is frequently prescribed for geriatrics (Prakash et al., 2014).

1.2 PROBLEM STATEMENT

Despite the availability of sustained release formulations of carbamazepine, these formulations are not designed for pediatric patients. Pediatric patients with epilepsy need to take carbamazepine suspension divided into two or four times a day for long duration (Wolters Kluwer Health, 2017). There are no available marketed sustained release dosage forms to be used for pediatrics. The available dosage form is only (carbamazepine suspension) giving no options for those patients or their caregivers. Providing sustained release formulation of CBZ may help pediatrics in administering the drug with more convenience. The new sustained release dosage form should be flexible in dosing (mg drug per body weight) and suitable for pediatrics of different ages. For these reasons, chewable tablets and dispersible tablets may not achieve the

desired criteria. Instead, oral jellies that appeared as new dosage form might be a potential candidate.

1.3 HYPOTHESIS

CBZ can be prepared for pediatric-suitable sustained release jelly formulation. The formulated oral jelly has similar release profile as the reference.

1.4 OBJECTIVE

General objective:

To formulate CBZ in sustained release oral jelly formulation, suitable for pediatric use.

Specific objectives:

1. To fabricate sustained release CBZ microparticles by a solvent evaporation method using ethylcellulose polymer.
2. To characterize CBZ loaded microparticles for their particle size, encapsulating efficiency, *in vitro* drug release, morphology study, HPLC, ATR-FTIR, and DSC.
3. To load CBZ microparticles in alginate beads and characterize it for beads size, morphology study, encapsulation efficiency, *in vitro* drug release, and HPLC.
4. To suspend the beads in the jelly vehicle and characterize it for the syneresis, rheology, homogeneity test, *in vitro* drug release, and stability study.

1.5 STUDY DESIGN

This project is divided into three main parts: first, is the fabrication of CBZ-loaded microparticles using EC as encapsulating polymer. These microparticles are optimized

to have sustained release profile similar to the commercially approved sustained release CBZ tablets. Since microparticle may have grittiness feeling in the mouth when taken orally, they were entrapped in alginate beads. Alginate beads have better mouth feeling, jelly texture and biocompatible. Hence, the second part is the preparation of alginate beads containing CBZ microparticles. The beads are designed so that they have minimal effect on the release profile of the microparticles. Finally, is the preparation of jelly base to suspend alginate beads. The jelly acts as a vehicle to suspend the beads, preventing them from settling down and giving pediatric-friendly texture to be administered. Similarly, the jelly was optimized to have minimal effect on the release of CBZ from the microparticle. Therefore, the final dosage form will have same release profile of the microparticles, which is like the commercially available CBZ tablets.

CHAPTER TWO

LITERATURE REVIEW

2.1 INTRODUCTION

Developing a new dosage form is a real challenge to the pharmaceutical researchers, especially when the dosage form targets pediatric population. Pediatrics differ from adults in the type of dosage forms and the doses of the medications which considered to be constant in the adults and depended on the body weight for pediatrics. There are a differences in the pharmacodynamic and pharmacokinetic properties as the pediatrics have grown and organ developing stage (Estabrook, Bouxsein, Pitluck, & Davis, 2000).

There are different age groups named according to pediatrics developmental stages of their population (Committee, 2006) like:

- Pre- newborn infants.
- Newborn infants aged (from 0 to 27) days.
- Infants and toddlers aged (1-23) months.
- Children aged (from 2 to 11) years.
- Adolescents aged (12-16 or 18) years.

2.2 PHARMACOLOGICAL DEVELOPMENT OF PEDIATRIC POPULATION

Children are growing and many physiological and pharmacological changes occurred during their life. Understanding those changes can give an idea to handle and manufacture the suitable medications. A brief summary is explained for absorption,

distribution, metabolism and renal elimination in pediatrics to understand the best way of bioavailability of any medication prescribed for their use and as follows (Committee, 2006):

2.2.1 Absorption

The different site of drug absorption of children can be explained by the following discussion:

2.2.1.1 Oral

In the neonatal stage, gastric pH is high with increasing of gastric emptying, therefore the rate of absorption for drugs administered orally is faster in older pediatrics than neonates and infants (Heimann, 1980).

2.2.1.2 Buccal

The permeability of mucosa considered to be higher in pediatrics than adults (Committee, 2006).

2.2.1.3 Topical

Pediatrics have large surface area compared to adults, therefore percutaneous absorption is more. Topical substances have potential absorption through the skin of pediatrics to reach blood circulation and body tissues and may cause toxicity (for example, adrenal suppression with topical corticosteroids). Epidermis layer in childhood is more perfused and hydrated than adults and stratum corneum is thinner (Committee, 2006; Monsour, Rabinovitch, & Dean, 1999).

2.2.1.4 Intramuscular

Due to the rich supply of blood capillaries in infants than older pediatrics and adults, the absorption will be greater in infants (Simons, Roberts, Gu, & Simons, 1998).

2.2.1.5 Pulmonary

Absorption through lungs mucosa can be useful but drugs administered locally are well absorbed in pediatrics but may produce systemic side effects (Committee, 2006).

2.2.1.6 Rectal

Suppositories can be used for infants and can give good absorption but they will be an issue for older pediatrics (Maeda, Nakano, Aoyama, Matsumoto, & Fujito, 2016).

2.2.1.7 Nasal

Intranasal is a useful route of administration for pediatrics and can be considered as good absorption route and more preferred for pediatrics than injection but irritation or “a runny nose” and pain may be produced by formulations. Nasal mucosa secretion can also influence the absorption (Maggio, 2016).

2.2.1.8 Distribution

Age-related changes can be found in body composition especially protein binding and the transport mechanism. In infancy blood-brain barrier (BBB) is considered as immature part of their body (Allegaert, Velde, & Anker, 2014).